Arbutus Biopharma - ABUS Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $4.33
  • Forecasted Upside: 48.91%
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$2.91
▼ -0.12 (-3.96%)

This chart shows the closing price for ABUS by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Arbutus Biopharma Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ABUS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ABUS

Analyst Price Target is $4.33
▲ +48.91% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for Arbutus Biopharma in the last 3 months. The average price target is $4.33, with a high forecast of $5.00 and a low forecast of $4.00. The average price target represents a 48.91% upside from the last price of $2.91.

This chart shows the closing price for ABUS for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Buy

The current consensus among 3 contributing investment analysts is to buy stock in Arbutus Biopharma. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/22/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/20/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/20/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/19/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/17/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/15/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/15/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/14/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/4/2024JMP SecuritiesReiterated RatingMarket Outperform ➝ Market Outperform$4.00Low
3/1/2024HC WainwrightLower TargetBuy ➝ Buy$6.00 ➝ $5.00Low
3/1/2024Chardan CapitalReiterated RatingBuy ➝ Buy$4.00Low
9/12/2023HC WainwrightReiterated RatingBuy ➝ Buy$6.00Low
8/4/2023Chardan CapitalReiterated RatingBuy ➝ Buy$6.00Low
8/4/2023HC WainwrightReiterated RatingBuy ➝ Buy$6.00Low
4/5/2023HC WainwrightReiterated RatingBuy$6.00Low
3/29/2023JMP SecuritiesReiterated RatingMarket Outperform$6.00Low
3/3/2023HC WainwrightReiterated RatingBuy$6.00Low
3/3/2023Chardan CapitalReiterated RatingBuy$6.00Low
11/10/2022HC WainwrightLower TargetBuy$7.50 ➝ $6.00Low
6/28/2022JMP SecuritiesLower TargetMarket Outperform$10.00 ➝ $9.00Low
3/14/2022HC WainwrightBoost TargetBuy$8.00 ➝ $8.50High
3/4/2022Chardan CapitalBoost TargetBuy$5.50 ➝ $6.00High
2/2/2022Jefferies Financial GroupUpgradeHold ➝ Buy$4.00 ➝ $5.00High
12/2/2021Chardan CapitalBoost TargetBuy$5.00 ➝ $5.50High
11/8/2021HC WainwrightLower TargetBuy$10.00 ➝ $8.00Low
11/8/2021JMP SecuritiesBoost TargetMarket Outperform$7.00 ➝ $9.00High
11/5/2021JMP SecuritiesReiterated RatingBuy$7.00High
11/4/2021Chardan CapitalReiterated RatingBuyMedium
10/17/2021Chardan CapitalReiterated RatingBuyHigh
8/31/2021Chardan CapitalReiterated RatingBuyLow
3/10/2021B. RileyLower TargetBuy$8.00 ➝ $7.00N/A
3/10/2021HC WainwrightReiterated RatingBuy$10.00Low
2/25/2021Jefferies Financial GroupInitiated CoverageHold$5.00High
12/17/2020HC WainwrightInitiated CoverageBuy$10.00Low
11/16/2020Chardan CapitalReiterated RatingBuy$5.00Low
8/28/2020Chardan CapitalReiterated RatingBuy$5.00Low
7/27/2020JMP SecuritiesInitiated CoverageOutperform$10.00 ➝ $8.00Medium
7/27/2020B. RileyBoost Target$6.00 ➝ $8.00Low
7/24/2020Robert W. BairdDowngradeOutperform ➝ NeutralHigh
5/19/2020WedbushUpgradeNeutral ➝ Outperform$2.00 ➝ $4.00High
5/19/2020B. RileyReiterated RatingBuy$6.00High
5/13/2020Chardan CapitalReiterated RatingBuy$5.00High
5/11/2020B. RileyReiterated RatingBuy$6.00High
3/27/2020Robert W. BairdLower TargetOutperform$8.00 ➝ $4.00High
3/5/2020Chardan CapitalUpgradeNeutral ➝ Buy$1.50 ➝ $5.00Low
2/19/2020Robert W. BairdInitiated CoverageOutperform$8.00Medium
2/10/2020B. RileyReiterated RatingBuy$6.00High
2/5/2020JMP SecuritiesUpgradeMarket Perform ➝ Outperform$10.00High
1/9/2020B. RileyBoost TargetBuy$3.00 ➝ $6.00Low
10/7/2019B. RileyLower TargetBuy$7.00 ➝ $3.00High
10/4/2019Echelon Wealth PartnersDowngradeHold ➝ SellLow
10/4/2019Chardan CapitalDowngradeBuy ➝ NeutralHigh
7/16/2019Chardan CapitalReiterated RatingBuy$5.00High
(Data available from 4/14/2019 forward)

News Sentiment Rating

0.19 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 7 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/17/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
10/17/2023
  • 5 very positive mentions
  • 6 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
11/16/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/16/2023
  • 2 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/15/2024
  • 2 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/14/2024
  • 4 very positive mentions
  • 17 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
3/15/2024
  • 3 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
4/14/2024

Current Sentiment

  • 3 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
Arbutus Biopharma logo
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
Read More

Today's Range

Now: $2.91
Low: $2.90
High: $3.03

50 Day Range

MA: $2.75
Low: $2.36
High: $3.12

52 Week Range

Now: $2.91
Low: $1.69
High: $3.29

Volume

666,195 shs

Average Volume

1,889,049 shs

Market Capitalization

$522.32 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.03

Frequently Asked Questions

What sell-side analysts currently cover shares of Arbutus Biopharma?

The following Wall Street sell-side analysts have issued reports on Arbutus Biopharma in the last year: Chardan Capital, HC Wainwright, JMP Securities, and StockNews.com.
View the latest analyst ratings for ABUS.

What is the current price target for Arbutus Biopharma?

3 Wall Street analysts have set twelve-month price targets for Arbutus Biopharma in the last year. Their average twelve-month price target is $4.33, suggesting a possible upside of 48.9%. HC Wainwright has the highest price target set, predicting ABUS will reach $5.00 in the next twelve months. JMP Securities has the lowest price target set, forecasting a price of $4.00 for Arbutus Biopharma in the next year.
View the latest price targets for ABUS.

What is the current consensus analyst rating for Arbutus Biopharma?

Arbutus Biopharma currently has 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ABUS will outperform the market and that investors should add to their positions of Arbutus Biopharma.
View the latest ratings for ABUS.

What other companies compete with Arbutus Biopharma?

How do I contact Arbutus Biopharma's investor relations team?

Arbutus Biopharma's physical mailing address is 701 VETERANS CIRCLE, WARMINSTER PA, 18974. The biopharmaceutical company's listed phone number is (267) 469-0914 and its investor relations email address is [email protected]. The official website for Arbutus Biopharma is www.arbutusbio.com. Learn More about contacing Arbutus Biopharma investor relations.